Anuh Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2025, recommended Final Dividend of Rs. 1.50 per equity share.

EBITDA margin compressionRevenue growth above 20%Results View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹100.50

prior close

₹102.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+2.0% vs market

Pharmaceuticals peers, median of 148sector+0.4%+2.2% vs sector

On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+1.5

15m

+1.4

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6+0.6+2.0+0.4+2.2

Next day

+5.0+0.5+4.5+0.3+4.6

+6.0+0.8+5.2+0.5+5.5

+6.0+1.2+4.8+1.0+5.0

+4.8+1.5+3.3+0.6+4.2

+8.6+1.6+7.0-0.1+8.7

+7.5+1.8+5.7+0.1+7.4

15d

+5.8+3.3+2.5+1.5+4.3

+3.3+3.1+0.2-1.2+4.5

-3.5+2.3-5.8+0.9-4.4

-12.9+0.2-13.1-1.6-11.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma's Board met on May 23, 2025, and approved audited results for Q4 and FY ending March 31, 2025, along with a 1:1 bonus issue and a final dividend of Rs. 1.50 per share on the post-bonus capital (30% on face value), subject to shareholder approval. FY25 revenue from operations rose modestly to Rs. 66,151 lakhs from Rs. 64,700 lakhs last year, but profit after tax fell about 21% to Rs. 4,735 lakhs from Rs. 6,006 lakhs, and EBITDA margin compressed sharply to 10.64% from 13.48%. The auditor Jayantilal Thakkar & Co. issued an unmodified opinion on the results. The bonus, if approved by postal ballot, will double the share count from about 5.01 crore to 10.02 crore equity shares. AGM is scheduled for August 22, 2025. Directors Ritesh Shah and Vivek Shah were re-appointed as Joint Managing Directors for another 5-year term starting January 2026. Free reserves stood at Rs. 300.85 crore as of March 31, 2025, sufficient to fund the bonus.

Likely market impact

Shareholders benefit from a 1:1 bonus (effectively doubling their shareholding) plus a Rs. 1.50 dividend per share, but the underlying earnings decline and sharp EBITDA margin compression may temper near-term sentiment despite the shareholder rewards.

By the numbersStandalone · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹198.1 Cr	₹163.9 Cr	+20.9%
Operating profit	₹15.88 Cr	₹16.90 Cr	−6.0%
Profit after tax	₹12.46 Cr	₹15.36 Cr	−18.9%
EBITDA margin	9.4%	11.7%	−2.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.